Journal profile · Medicine-Psychiatry and Mental Health
Alzheimer's and Dementia: Translational Research and Clinical Interventions
ISSN 2352-8737 · Wiley-Blackwell · United States
Alzheimer's and Dementia: Translational Research and Clinical Interventions: CAS Zone 2 · Medicine (2025 upgraded edition); fully open access; APC about USD 2,670; median 108 days to acceptance (99 articles, last 24 months); 173 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Alzheimer's and Dementia: Translational Research and Clinical Interventions is published by Wiley-Blackwell and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments and Geriatric Care and Nursing Homes, together about 60.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access journal from the Alzheimer's Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer's disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications.The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development.For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer's disease.The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.The forms of interventions that are of special interest include, but not limited to: drugs, biologics, devices, and psychotherapeutic, psychosocial, and non-pharmacological modalities. The types of research considered may range from animal model, early discovery and preclinical development to late-stage clinical trials and health technology assessment. Key topics for the journal include a broad array questions or approaches to research such as discovery, related-early protein chemistry, cell biology, mechanistic/exploratory/therapeutic animal models, therapeutic development, clinical pharmacology, preclinical studies, and the application of
From the journal's Aims & Scope
Research area (LetPub): Medicine-Psychiatry and Mental Health
Editor-in-chief Barry D. GreenbergPublisher website
Editorial board by country: 3 in mainland China (about 4%); most named United States 59, Mainland China 3, Canada 3, Brazil 3, United Kingdom 2 (80 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Dementia and Cognitive Impairment ResearchMedicine35.3%
- Alzheimer's disease research and treatmentsMedicine21.7%
- Geriatric Care and Nursing HomesHealth Professions3.4%
- Functional Brain Connectivity StudiesNeuroscience3.1%
- Cholinesterase and Neurodegenerative DiseasesMedicine2.9%
- Ethics in Clinical ResearchMedicine2.6%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance2.6%
- Neurological Disease Mechanisms and TreatmentsNeuroscience2.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Neurosciences | Zone 2 |
| Minor | Clinical Neurology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Clinical Neurology | Zone 2 |
| Minor | Neurosciences | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
ESCIWeb of SciencePMCPubMedPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 10.2LetPub ·
- SJR 2026-06
- 1.92LetPub ·
- SNIP 2026-06
- 1.57LetPub ·
- h-index
- 86OpenAlex ·
- i10-index
- 610OpenAlex ·
- 2-year mean citedness
- 4.64OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 1,153 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 129 | 129 | 52 |
| 2025 | 173 | 173 | 834 |
| 2024 | 87 | 87 | 920 |
| 2023 | 71 | 71 | 1,426 |
| 2022 | 141 | 141 | 3,551 |
| 2021 | 111 | 111 | 3,594 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
108 daysMedian, submission to acceptance · P25–P75 84 days – 161 days
- Acceptance to online
- median 39 days (99 articles)
- Submission to online
- median 157 days
- Sample
- 99 articles with submission and acceptance dates (313 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,670 / GBP 1,940 / EUR 2,180 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,540 / EUR 2,080 / GBP 1,850 | — | — | |
| LetPub | USD 2,310 / GBP 1,680 / EUR 1,890 | Yes | — | |
| Publisher website | No APC | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted11, with length limits
- commentaryReview Articles:Comprehensive Reviews are commissioned papers by the editors to provide comprehensive and balanced coverage of a timely and/or controversial iss…main text ≤ 1,500 words
- hypothesisReview Articles:Comprehensive Reviews are commissioned papers by the editors to provide comprehensive and balanced coverage of a timely and/or controversial iss…Length not stated
- open-peer commentariesOpen-Peer Commentaries must include an abstract of approximately 300 words. Length of Open-Peer Commentaries may not exceed 1,500 words (excluding the abstract,…Length not stated
- opinionReview Articles:Comprehensive Reviews are commissioned papers by the editors to provide comprehensive and balanced coverage of a timely and/or controversial iss…Length not stated
- perspectiveReview Articles:Comprehensive Reviews are commissioned papers by the editors to provide comprehensive and balanced coverage of a timely and/or controversial iss…main text ≤ 5,000 words
- perspectivesPerspectives and Open-Peer Commentaries provide personal in-depth viewpoints, rather than a review, on hotly debated topics; controversial theoretical, research…Length not stated
- research articleReview Articles:Comprehensive Reviews are commissioned papers by the editors to provide comprehensive and balanced coverage of a timely and/or controversial iss…Length not stated
- research articlesResearch Articles cover hypothesis driven research or evidence-based validation studies in any of the following generic areas of study: Biology, Chemistry, Clin…Length not stated
- reviewReview Articles:Comprehensive Reviews are commissioned papers by the editors to provide comprehensive and balanced coverage of a timely and/or controversial iss…Length not stated
- review articleReview Articles:Comprehensive Reviews are commissioned papers by the editors to provide comprehensive and balanced coverage of a timely and/or controversial iss…main text ≤ 10,000 words
- viewpointReview Articles:Comprehensive Reviews are commissioned papers by the editors to provide comprehensive and balanced coverage of a timely and/or controversial iss…Length not stated
Policy excerpts from the journal's websiteData availability
- Data availability
Research in Context section required Model summary
Alzheimer's & Dementia: Translational Research & Clinical Interventions requires a section called “Research in Context”.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- Country or region
- United States
- Language
- English
- ISSN
- 2352-8737
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Alzheimer's and Dementia: Translational Research and Clinical Interventions
What CAS zone is Alzheimer's and Dementia: Translational Research and Clinical Interventions in?
In the 2025 upgraded edition of the CAS Journal Ranking, Alzheimer's and Dementia: Translational Research and Clinical Interventions is in Zone 2 of Medicine, and in Zone 2 of the minor category Neurosciences / Clinical Neurology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Alzheimer's and Dementia: Translational Research and Clinical Interventions?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 108 days (interquartile range 84–161 days); authors report an average review time of about 10 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Alzheimer's and Dementia: Translational Research and Clinical Interventions based?
Of the 80 board members whose country the journal's board page names, 3 (about 4%) are in mainland China; the countries named most often are United States (59), Mainland China (3) and Canada (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Alzheimer's and Dementia: Translational Research and Clinical Interventions?
According to LetPub and DOAJ records, Alzheimer's and Dementia: Translational Research and Clinical Interventions is indexed in Scopus and DOAJ. The journal's website also lists ESCI, Web of Science, PMC and PubMed; that list has not been checked against each database.
Is Alzheimer's and Dementia: Translational Research and Clinical Interventions open access, and what is the APC?
Alzheimer's and Dementia: Translational Research and Clinical Interventions is a fully open-access journal. APC about USD 2,670.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .